Vous venez de lire:

Auven Therapeutics and BELLUS Health announce completion of enrollment in the Phase III Confirmatory Study of KIACTA™ for the treatment of AA amyloidosis

Nouvelles fournies par

BELLUS Health Inc.

May 27, 2014, 17:00 ET